Physician profile
Christa Young
NPI 1518688092
$7,812.36
in general payments reported to CMS, 2019-2025
41 companies · $2,504 in 2025
The $2,504 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,932 · 2024: $2,377 · 2025: $2,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,787 · Consulting Fee: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,787.36 |
| Consulting Fee | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $907.00 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $800.13 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $628.52 | 2023-2025 | |
| Pfizer INC. | $619.43 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $570.37 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $547.93 | 2023-2025 | Rexulti, Nuedexta |
| Kowa Pharmaceuticals America, INC. | $322.10 | 2023-2025 | Seglentis, Zoryve, Livalo |
| Merck Sharp & Dohme LLC | $311.95 | 2023-2025 | Verquvo, Belsomra, Gardasil 9 |
| Glaxosmithkline, LLC. | $294.04 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $275.65 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Vanda Pharmaceuticals INC. | $217.11 | 2025 | Fanapt, Hetlioz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.56 | 2023-2025 | Jardiance |
| Collegium Pharmaceutical, INC. | $176.52 | 2023-2025 | Belbuca |
| Phathom Pharmaceuticals, INC. | $172.52 | 2025 | Voquezna |
| Eisai INC. | $164.13 | 2023-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $151.75 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $138.21 | 2023-2025 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.02 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $112.66 | 2023-2024 | Xarelto |
| Corium, LLC | $102.39 | 2023 | Adlarity, Azstarys |
| Amgen INC. | $96.15 | 2023-2025 | Otezla, Repatha, Repatha |
| Sumitomo Pharma America, INC. | $95.41 | 2024-2025 | Gemtesa |
| Ironwood Pharmaceuticals, INC | $87.36 | 2023-2024 | Linzess |
| Idorsia Pharmaceuticals US INC | $77.99 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $76.78 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $70.19 | 2023-2024 | |
| Shield Therapeutics INC | $68.58 | 2023-2025 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $62.23 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $47.97 | 2025 | Eliquis |
| Paratek Pharmaceuticals, INC. | $46.97 | 2023-2024 | Nuzyra |
| Ardelyx, INC. | $39.85 | 2025 | Ibsrela |
| Esperion Therapeutics, INC. | $33.76 | 2023-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $29.25 | 2023 | |
| Baxter Healthcare | $25.00 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Antares Pharma, INC. | $24.43 | 2023 | Nocdurna, Tlando, Xyosted |
| Halozyme INC | $21.44 | 2023 | |
| Daiichi Sankyo INC. | $17.89 | 2023 | Injectafer |
| Xeris Pharmaceuticals, INC. | $17.84 | 2023 | Gvoke Hypopen |
| Lexicon Pharmaceuticals, INC. | $16.74 | 2023 | Inpefa |
| Edwards Lifesciences Corporation | $15.36 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Impel Pharmaceuticals INC. | $15.18 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christa Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.